Overview

• The standard applies solely to NHS-funded patients, excluding the estimated 1.5 million people who pay privately for GLP-1 injections like Wegovy and Mounjaro.
• Around 240,000 individuals with the greatest clinical need are expected to receive Mounjaro on the NHS over the next three years.
• NICE cited research showing many patients regain significant weight within months of stopping treatment without ongoing support.
• Pharmacies and community services are urged to embed behavioural interventions such as self-monitoring tools, peer groups and family-led programmes into their aftercare.
• The quality standard aligns with the NHS Ten-Year Plan by shifting focus from reactive treatment to long-term prevention and health maintenance.